Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079376 | 0.88 | NPC1 (0.74) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1986154 | 0.88 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2061754 | 0.87 | ALOX5 (0.77) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2633343 | 0.87 | ALOX5 (0.77) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31680508 | 0.86 | NPC1 (0.93) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9423776 | 0.86 | ALOX5 (0.75) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12218328 | 0.85 | MEN1 (0.60) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8392815 | 0.84 | MEN1 (0.55) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12479231 | 0.83 | MAPT (0.64) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4248077 | 0.83 | NPC1 (1.00) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187467-B2 | 2-phenyl benzothiazole linked imidazole compounds as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150141657-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-05-21 | — | — | US | disclosed |
| EP-2556072-B1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-05-21 | — | — | EP | disclosed |
| EP-2556072-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2012110959-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-23 | — | — | WO | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | KMT2A 632/4885MEN1 1233/4885RAB9A 733/4885 |
| US-20150141657-A1 | 2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NFE2L2, TPT1, CCNT1 | KMT2A 305/4885MEN1 2781/4885RAB9A 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.